相关实验视频
Updated: May 11, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
用帕蒂西兰治疗多神经病的遗传性转基因氨基粉症的五年结果:随机临床试验与开放式扩展
David Adams1, Jonas Wixner2, Michael Polydefkis3
1Department of Neurology, Centre Hospitalo Universitaire Bicêtre, Assistance Publique Hopitaux de Paris, Université Paris-Saclay, L'Institut national de la santé et de la recherche médicale U-1195, Le Kremlin Bicêtre Cedex, France.
对具有多神经病变 (hATTR-PN) 的遗传性转基因氨基粉症的帕蒂西兰治疗显示了适度的长期益处和5年可接受的安全性. 用RNAi疗法的早期干预对于管理hATTR-PN至关重要.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 遗传性转基因氨基化与多神经病变 (hATTR-PN) 缺乏RNA干扰 (RNAi) 疗法的长期疗效和安全性数据.
- 帕蒂西兰是一种用于hATTR-PN的RNAi治疗药物.
研究的目的:
- 提供帕蒂西兰在hATTR-PN.成年患者中长期有效性和安全性数据.
- 评估帕蒂西兰对残疾,神经病变,营养和生活质量的长期影响.
主要方法:
- 全球APOLLO随机临床试验和第二阶段OLE研究的开放式扩展研究.
- 招募了211名hATTR患者,其中138人完成了长达5年的随访.
- 帕蒂西兰每3周内静脉注射0.3毫克/公斤.
主要成果:
- 在5年后,多神经病障碍 (PND) 评分在65%的患者中保持稳定或改善.
- 平均修改体质指数 (mBMI) 增加,而生活质量得分 (诺福克QOL-DN,R-ODS) 显示了适度的变化.
- 导致戒断的不良事件发生在22.3%的患者中; 19.4%在研究期间死亡.
结论:
- 帕蒂西兰在hATTR-PN.患者中显示出适度的长期疗效和可接受的安全性.
- 早期启动hATTR-PN治疗非常重要.
- RNAi疗法显示出治疗各种疾病的潜力.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
03:53Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management
Published on: March 15, 2024
相关概念视频
Treatment Resistant Cancers
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation